XORTX Therapeutics
XRTX
5 hedge funds and large institutions have $29.2K invested in XORTX Therapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 → 5 (+1)
0.06% less ownership
Funds ownership: 0.17% → 0.11% (-0.06%)
56% less capital invested
Capital invested by funds: $66K → $29.2K (-$36.7K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$33K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$59.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $23.3K | +$33K | +2,467 | New |
|
2
Osaic Holdings
Scottsdale,
Arizona
| $2.19K | – | – | – |
|
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$3.28K | +245 | New |
|
4
JP Morgan Chase
New York
| $1.21K | – | – | – |
|
|
CA
5
Clearstead Advisors
Cleveland,
Ohio
| $527 | – | – | – |
|
|
6
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$59.8K | -2,999 | Closed |
|
XRTX Hedge Fund Activity: Q2 2024 in Review
5 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q2 2024, worth a combined $29.2K — down 56% from $66K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XRTX positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $33K. The largest seller was Bank of Montreal, exiting entirely with an estimated $59.8K sold.
- 5 institutional investors held XORTX Therapeutics (XRTX) as of Q2 2024, up from 4 in Q1 2024.
- Funds reported $29.2K of XORTX Therapeutics stock for Q2 2024, down 56% quarter-over-quarter.
- 2 funds opened new XORTX Therapeutics positions in Q2 2024 and 1 closed out, a net change of +1 holder.
- The largest XORTX Therapeutics buyer in Q2 2024 was Citadel Advisors, an estimated $33K added.
- The largest XORTX Therapeutics seller in Q2 2024 was Bank of Montreal, an estimated $59.8K sold.
Based on aggregated 13F filings for Q2 2024.